エフェクター制御性T細胞におけるニボルマブ受容体占有率は臨床的有用性を予測する(Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit)

Hosonuma Masahiro, Hirasawa Yuya, Kuramasu Atsuo, Murayama Masakazu, Narikawa Yoichiro, Toyoda Hitoshi, Baba Yuta, Isobe Junya, Funayama Eiji, Tajima Kohei, Shida Midori, Hamada Kazuyuki, Tsurui Toshiaki, Ariizumi Hirotsugu, Ishiguro Tomoyuki, Suzuki Risako, Ohkuma Ryotaro, Kubota Yutaro, Horiike Atsushi, Sambe Takehiko, Tsuji Mayumi, Wada Satoshi, Kiuchi Yuji, Kobayashi Shinichi, Tsunoda Takuya, Yoshimura Kiyoshi

Cancer Science   115 ( 3 )   752 - 762   2024年3月（ ISSN:1347-9032 ）

Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease. 国際共著

Kubota Y, Aoki Y, Masaki N, Obara K, Hamada K, Han Q, Bouvet M, Tsunoda T, Hoffman RM.

Biochemical and Biophysical Research Communications   ( 695 )   149418   2024年2月（ ISSN:0006291X ）

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors

Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S.

Frontiers in Immunology   14   1260492   2023年9月

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy

Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S.

Oncology Letters   26 ( 3 )   381   2023年7月（ ISSN:17921074 ）

Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary

Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Ariizumi H, Kubota Y, Horiike A, Yoshimura K, Wada S, Yamochi T, Tsunoda T.

Frontiers in Oncology   13   1231986   2023年7月

Old-age-induced obesity reversed by a methionine-deficient diet or oral administration of recombinant methioninase-producing Escherichia coli in C57BL/6 mice 国際共著

Kubota Y, Han Q, Reynoso J, Aoki Y, Masaki N, Obara K, Hamada K, Bouvet M, Tsunoda T, Hoffman RM.

Aging (Albany NY)    15 ( 11 )   4642 - 4648   2023年6月

Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment 国際共著

Kubota Y, Han Q, Aoki Y, Masaki N, Obara K, Hamada K, Hozumi C, Wong ACW, Bouvet M, Tsunoda T, Hoffman RM.

Cancer Diagnosis & Prognosis   3 ( 3 )   272 - 281   2023年5月

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K.

Frontiers in Immunology   14   1164724   2023年5月

Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers

Muto S, Enta A, Maruya Y, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Hamada K, Suzuki H.

Biomedicines   11 ( 1 )   190   2023年1月

Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction. 国際共著

Kubota Y, Han Q, Masaki N, Hozumi C, Hamada K, Aoki Y, Obara K, Tsunoda T, Hoffman RM.

Anticancer Research   42 ( 12 )   5819 - 5823   2022年12月（ ISSN:0250-7005 ）

腸内細菌叢からみたNSCLCにおけるICI治療

MSD NSCLC Web Seminar 2023   2023年6月  

バイオマーカーに基づく肺がん薬物療法の選択～ゲノム検査と免疫染色の役割～

第1回秋田県めんけセミナー   2023年6月  

固形がん患者における抗PD-1抗体の治療有効例と免疫学的有害事象発症例に多い腸内細菌の同定.

第35回日本バイオセラピィ学会学術集会総会   2022年12月